FDA approves a two-pill combination for some men with advanced prostate cancer
Published
On Oct. 26 the FDA cleared Pfizer's Talzenna taken with Xtandi for men whose metastatic prostate cancer carries certain DNA-repair gene changes found by an approved test, even before hormone treatment stops working. In a trial of about 600 men, the pair cut the risk of the cancer worsening or death by about half compared with Xtandi alone. Ask your oncologist whether genetic testing of your tumor makes sense.
Source: Pharmacy Times
This is a plain-language summary. Read the original source for full details.